Key Financial Results (in lakhs)
Quarter Ended 30.06.2026 (Unaudited):
- Revenue from Operations: Not reported (shown as ÷)
- Other Income: ₹8.34
- Total Income: ₹8.34
- Total Expenses: ₹(13.39) [negative expense]
- Profit before tax: ₹21.73
- Tax expense: Not applicable (no tax reported)
- Profit for the period: ₹21.73
- Other Comprehensive Income: ₹17.46
- Total Comprehensive Income: ₹39.19
- Earnings per share (Basic): ₹0.35
- Earnings per share (Diluted): ₹0.35
- Paid-up equity share capital: ₹627.26 (Face Value ₹10 each)
Comparative Financials:
- Quarter Ended 30.06.2025: Revenue ₹506.20, Profit ₹48.47, EPS ₹0.77
- Year Ended 31.03.2026: Revenue ₹209.00, Profit ₹20.32, EPS ₹0.32
- Year Ended 31.03.2025: Revenue ₹82.62, Profit ₹24.55, EPS ₹0.39
Operational Context
The results pertain to trading in Pharma/Pesticides Segment, which is the business segment of the Company.
Auditor Review
M/s Verma Mehta & Associates, Chartered Accountants (Firm Registration No: 112118W), conducted a review of the interim financial results pursuant to Regulation 33 of SEBI Listing Regulations. Partner Rohit Rahalkar (M.N. 139232) issued an unmodified review report stating that nothing has come to their attention that causes them to believe the Statement contains any material misstatement. The review was conducted in accordance with Standard on Review Engagements (SRE) 2410 issued by ICAI.
Meeting Details
The Board meeting commenced at 12:30 PM and concluded at 1:10 PM on 13th August, 2026.